诺诚健华(688428.SH)公告称,公司上半年实现营业收入7.31亿元,同比增长74.26%;归母净亏损3009.14万元,上年同期亏损2.62亿元。报告期内,营业收入较上年同期增加,主要系奥布替尼销售量持续增加及达成授权许可确认相关收入所致,其中药品销售收入增长53.47%。
诺诚健华(688428.SH)公告称,公司上半年实现营业收入7.31亿元,同比增长74.26%;归母净亏损3009.14万元,上年同期亏损2.62亿元。报告期内,营业收入较上年同期增加,主要系奥布替尼销售量持续增加及达成授权许可确认相关收入所致,其中药品销售收入增长53.47%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.